Skip to main content
. 2011 Jan 21;9:14. doi: 10.1186/1479-5876-9-14

Table 2.

Patient characteristics of HIV-infected individuals according to type of resistance test (RT)

All GRT GRT + rPRT
Total tests - n 1158 937 221

Male - % 69.4 68.8 72.0

Age - median [IQR] 41 [36-47] 41 [36-47] 40 [36-47]

Caucasian - % 79.5 79.9 77.8

HIV transmission group - %
 Homosexual 39.5 40.7 34.4
 Heterosexual 38.0 37.3 41.2
 IDU 18.7 18.6 19.5
 Other 3.8 3.5 5.0

Current IDU or in drug maintenance program - % 12.0 11.9 12.7

Baseline HIV-1 RNA (copies/mL)†- %
 Log RNA - Median [IQR] 4.2 [3.2-4.9] 4.2 [3.2-4.9] 4.2 [3.3-4.9]
 = 50 2.6 3.0 0.9
 51 - 500 10.6 10.6 10.7
 501 - 1000 5.0 5.0 5.1
 >1000 81.8 81.4 83.3

Baseline CD4 cell count (109)† - %
 Median [IQR] 261 [168-387] 260 [166-387] 266 [180-390]
 <200 33.1 33.4 32.1
 200 - 349 36.5 36.8 34.9
 350 - 499 17.9 17.4 20.1
 = 500 12.6 12.5 12.9

Hepatitis C¶ - % 3.2 3.8 0.5

AIDS - % 29.2 29.4 28.5

Number of previous ART regimens
 Median [IQR] 2 [0-6] 2 [0-6] 2 [0-5]

Treatment status at time of RT - %
 Naïve 30.2 29.5 33.5
 Off treatment 14.3 15.5 9.1
 Current 55.5 55.1 57.5

ART after RT - %
 NNRTI 26.3 24.8 32.6
 PI non-boosted 5.9 5.9 5.9
 PI boosted 58.8 60.7 50.7
 Triple Nucleoside/Other 9.1 8.6 10.9

Maximum missed doses of ART# -%
 0 49.9 51.2 45.9
 1 15.1 13.5 20.2
 2 12.9 13.5 11.0
 >2 22.2 21.9 22.9

Missed 2 consecutive doses of ART# - % 19.2 19.1 19.4
SHCS centre at time of RT - %
 Basel 12.2 3.0 51.1
 Bern 14.8 10.8 31.7
 Geneva 19.3 23.8 0
 Lausanne 10.0 12.4 0
 Lugano 3.1 3.4 1.8
 St. Gallen 4.2 2.2 12.2
 Zurich 36.5 44.4 3.2

¶ Active/chronic hepatitis C

† Baseline is the time of RT. Labs closest to before or after the RT.

# In the year prior to RT.

RT = resistance test, GRT = genotypic RT, rPRT = replicative phenotypic RT, ART = antiretroviral therapy, IQR = interquartile range, IDU = intravenous drug use,